| Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial FL Locke, A Ghobadi, CA Jacobson, DB Miklos, LJ Lekakis, OO Oluwole, ... The lancet oncology 20 (1), 31-42, 2019 | 1879 | 2019 |
| Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma LH Sehn, AF Herrera, CR Flowers, MK Kamdar, A McMillan, M Hertzberg, ... Journal of Clinical Oncology 38 (2), 155, 2020 | 679 | 2020 |
| Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma AF Herrera, AJ Moskowitz, NL Bartlett, JM Vose, R Ramchandren, ... Blood, The Journal of the American Society of Hematology 131 (11), 1183-1194, 2018 | 324 | 2018 |
| Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity CA Jacobson, BD Hunter, R Redd, SJ Rodig, PH Chen, K Wright, ... Journal of Clinical Oncology 38 (27), 3095, 2020 | 261 | 2020 |
| Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a Center for International Blood and Marrow Transplant … N Ghosh, R Karmali, V Rocha, KW Ahn, A DiGilio, PN Hari, V Bachanova, ... Journal of Clinical Oncology 34 (26), 3141, 2016 | 246 | 2016 |
| Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial SS Neelapu, M Dickinson, J Munoz, ML Ulrickson, C Thieblemont, ... Nature medicine 28 (4), 735-742, 2022 | 177 | 2022 |
| Relapsed or refractory double-expressor and double-hit lymphomas have inferior progression-free survival after autologous stem-cell transplantation AF Herrera, M Mei, L Low, HT Kim, GK Griffin, JY Song, RW Merryman, ... Journal of Clinical Oncology 35 (1), 24, 2017 | 177 | 2017 |
| PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation P Armand, YB Chen, RA Redd, RM Joyce, J Bsat, E Jeter, RW Merryman, ... Blood, The Journal of the American Society of Hematology 134 (1), 22-29, 2019 | 160 | 2019 |
| Magnetic resonance imaging captures the biology of ductal carcinoma in situ LJ Esserman, AS Kumar, AF Herrera, J Leung, A Au, YY Chen, DH Moore, ... Journal of clinical oncology: official journal of the American Society of …, 2006 | 152 | 2006 |
| Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results RH Advani, AJ Moskowitz, NL Bartlett, JM Vose, R Ramchandren, ... Blood, The Journal of the American Society of Hematology 138 (6), 427-438, 2021 | 141 | 2021 |
| Hodgkin lymphoma, version 2.2020, NCCN clinical practice guidelines in oncology RT Hoppe, RH Advani, WZ Ai, RF Ambinder, P Armand, CM Bello, ... Journal of the National Comprehensive Cancer Network 18 (6), 755-781, 2020 | 129 | 2020 |
| Sequence-based discovery of Bradyrhizobium enterica in cord colitis syndrome AS Bhatt, SS Freeman, AF Herrera, CS Pedamallu, D Gevers, F Duke, ... New England Journal of Medicine 369 (6), 517-528, 2013 | 128 | 2013 |
| Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data LH Sehn, M Hertzberg, S Opat, AF Herrera, S Assouline, CR Flowers, ... Blood advances 6 (2), 533-543, 2022 | 111 | 2022 |
| A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma NL Bartlett, AF Herrera, E Domingo-Domenech, A Mehta, A Forero-Torres, ... Blood, The Journal of the American Society of Hematology 136 (21), 2401-2409, 2020 | 105 | 2020 |
| Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma SS Neelapu, CA Jacobson, A Ghobadi, DB Miklos, LJ Lekakis, ... Blood, The Journal of the American Society of Hematology 141 (19), 2307-2315, 2023 | 104 | 2023 |
| PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL P Dreger, A Sureda, KW Ahn, M Eapen, C Litovich, H Finel, A Boumendil, ... Blood advances 3 (3), 360-369, 2019 | 98 | 2019 |
| Post-marketing use outcomes of an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, axicabtagene ciloleucel (Axi-Cel), for the treatment of large B cell lymphoma (LBCL … MC Pasquini, FL Locke, AF Herrera, T Siddiqi, A Ghobadi, KV Komanduri, ... Blood 134, 764, 2019 | 93 | 2019 |
| Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission M Shadman, M Pasquini, KW Ahn, Y Chen, CJ Turtle, P Hematti, ... Blood, The Journal of the American Society of Hematology 139 (9), 1330-1339, 2022 | 78 | 2022 |
| Cord colitis syndrome in cord-blood stem-cell transplantation AF Herrera, G Soriano, AM Bellizzi, JL Hornick, VT Ho, KK Ballen, ... New England Journal of Medicine 365 (9), 815-824, 2011 | 77 | 2011 |
| Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL. LH Sehn, M Kamdar, AF Herrera, A McMillan, C Flowers, WS Kim, TM Kim, ... Journal of Clinical Oncology 36 (15_suppl), 7507-7507, 2018 | 73 | 2018 |
